Get the Stockscreener App
5.31
2.39%
-0.13
After Hours:
5.28
-0.03
-0.56%
Annexon Inc stock is traded at $5.31, with a volume of 2.18M.
It is down -2.39% in the last 24 hours and down -15.18% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.44
Open:
$5.45
24h Volume:
2.18M
Relative Volume:
0.86
Market Cap:
$870.00M
Revenue:
-
Net Income/Loss:
$-206.69M
P/E Ratio:
-3.9174
EPS:
-1.3555
Net Cash Flow:
$-186.49M
1W Performance:
+1.92%
1M Performance:
-15.18%
6M Performance:
+24.36%
1Y Performance:
+157.77%
1-Day Range:
$5.25
$5.565
1-Week Range:
$4.835
$5.565
52-Week Range:
$1.85
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.31 | 891.30M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Moomoo
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%) - Stock Titan
ANNX Price Today: Annexon, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Annexon, Inc.common stock (NQ: ANNX - FinancialContent
Annexon Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference - sharewise.com
Director William Carson Acquires Additional Shares of Annexon In - GuruFocus
Director adds Annexon (ANNX) shares in Rule 10b5-1 plan purchase - Stock Titan
ANNX: Late-stage neuroinflammatory therapies show strong efficacy, with global filings and robust pipeline - TradingView
Annexon (NASDAQ:ANNX) Upgraded by The Goldman Sachs Group to "Hold" Rating - MarketBeat
Goldman Sachs initiates coverage of Annexon (ANNX) with neutral recommendation - MSN
ANNX Initiated Coverage by Goldman Sachs -- Price Target Set at $7.00 - GuruFocus
HC Wainwright Predicts Annexon's Q2 Earnings (NASDAQ:ANNX) - MarketBeat
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty - Investing.com Canada
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS - Investing News Network
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS - GlobeNewswire Inc.
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
HC Wainwright Has Optimistic View of Annexon FY2030 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN) - The Globe and Mail
Annexon (NASDAQ:ANNX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Annexon Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Annexon, Inc. Stock 12‑Month Price Target Raised to $14.38, Implies 160% Upside - TradingView
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones - Investing News Network
Annexon (NASDAQ: ANNX) trims loss, details GBS and GA drug pipeline - Stock Titan
Annexon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Annexon (NASDAQ: ANNX) trims Q1 2026 loss, targets key GA and GBS milestones - Stock Titan
Annexon targets Q4 data for vision drug in 8M-patient eye disease - Stock Titan
The competitive edge that makes Annexon (ANNX) special (-0.26%) 2026-05-06Momentum Picks - Newser
Annexon to Present at the Bank of America Securities Health Care Conference 2026 - Investing News Network
Annexon to Present at Bank of America Securities Health Care Conference on May 6, 2026 - geneonline.com
EarningsChartMill - ChartMill
Annexon | DEFA14A: Others - Moomoo
Annexon | ARS: Annual Report to Security Holders - Moomoo
ANNX: Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026 - TradingView
Annexon (NASDAQ: ANNX) proxy asks approval to boost share authorization and elect directors - Stock Titan
Annexon stock rises after director purchases shares - MSN
Annexon presents four studies on Guillain-Barre syndrome disease burden and targeted therapies - Traders Union
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential - Yahoo Finance
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):